Adeno-associated virus serotype 2 (AAV2) gene therapy for wet AMD — the single-administration genetic medicine delivering sustained anti-angiogenic protein expression (sFLT01, aflibercept, ranibizumab variants) directly to retinal pigment epithelium eliminating the need for monthly intravitreal injections — represents the most transformative therapeutic modality in the AMD treatment...